CD163 and COVID-19: An investigation of the pulmonary immune responses and lung pathology in two cohorts of patients with COVID-19 acute respiratory distress syndrome (ARDS) revealed in the lung an accumulation of CD163+ monocyte-derived macrophages that acquired a pro-fibrotic transcriptional phenotype during COVID-19 ARDS and thus probably contributed to the exacerbated fibro-proliferative response in COVID-19-associated ARDS [113].